Diversity and Distribution Patterns of Endemic Medicinal and Aromatic Plants of Iran: Implications for Conservation and Habitat Management

Iran, with its unique climatic and topographic conditions, is home to about 8200 species of vascular plants. Approximately 2300 of the 8200 species are popularly characterized as medicinal or aromatic. Here, we compile information about the endemic medicinal and aromatic plants (MAPs) of Iran and map their distributions. Our survey found 180 endemic species of MAPs, belonging to 10 families and 30 genera. The majority of species are found in Lamiaceae, Fabaceae, and Apiaceae, with 86, 30, and 18 species, respectively. Approximately 70% of these plants have been recorded in the 10 provinces of Esfahan, Kerman, Fars, Tehran, Chaharmahal va Bakhtiari, East Azarbaijan, Lorestan, West Azarbaijan, Hamadan, and Mazandaran. These provinces are located in the Iran-o-Turanian region, one of the three major phytogeographic regions in Iran, which covers five areas of endemism (i.e., Azarbaijan, Zagros, Kopet Dagh-Khorassan, Alborz, and Central Alborz). So, Iran-o-Turanian region is the main center of diversity for the Iranian endemic MAPs. The north, center and western parts of Iran are rich in MAPs and could be considered as the dominant biodiversity hotspots of Iran more seemingly due to the diverse climatic and geographic assortment which generates the highest frequency and distribution of MAPs. Many of these MAPs are at the edge of extinction due to the unwise, unscientific harvesting and/or global climate change. Therefore, there is an urgent need to conserve and propagate some of these important MAPs to save them from extinction and also to ensure the availability of raw materials for their use and future research into their efficacy. Furthermore, identifying the areas of endemism (AEs) is an essential part of ongoing regional conservation management programs in Iran and worldwide

Replacement of ALK inhibitors as an effective strategy for reducing drug toxicity in non-small cell lung cancer patients with ALK gene rearrangement

This case report examines the effects of replacement of anaplastic lymphoma kinase inhibitor (ALKi) as a strategy to reduce drug toxicity in patients with non-small cell lung cancer (NSCLC) with ALK gene rearrangements. A 61-year-old female patient with lung adenocarcinoma encountered difficulties in ALK abnormalities diagnosis: the expression of abnormal ALK protein was not detected by the immunohistochemistry (IHC) assay, but ALK gene rearrangement was present in next generation sequencing (NGS) and fluorescence in situ hybridization (FISH) assays. The patient was initially treated with second-generation ALKi (alectinib). However, the patient experienced severe hepatotoxicity. She was successfully switched to brigatinib (another second-generation ALK inhibitor). During brigatinib therapy, a transient increase in creatinine kinase concentration was observed, which required brigatinib dose reduction. Effectiveness of both anti-ALK agents was observed (partial response to treatment, followed by disease stabilization). This case report illustrates the difficulties in diagnosing ALK gene rearrangements and the possibility of replacing ALK inhibitors without compromising treatment efficacy.

Morphological, anatomical, and phytochemical studies of Carlina acaulis L. cypsela

Carlina acaulis L. has a long tradition of use in folk medicine. The chemical composition of the roots and green parts of the plant is quite well known. There is the lowest amount of data on the cypsela (fruit) of this plant. In this study, the microscopic structures and the chemical composition of the cypsela were investigated. Preliminary cytochemical studies of the structure of the Carlina acaulis L. cypsela showed the presence of substantial amounts of protein and lipophilic substances. The chemical composition of the cypsela was investigated using spectrophotometry, gas chromatography with mass spectrometry, and high-performance liquid chromatography with spectrophotometric and fluorescence detection. The cypsela has been shown to be a rich source of macro- and microelements, vegetable oil (25%), α-tocopherol (approx. 2 g/kg of oil), protein (approx. 36% seed weight), and chlorogenic acids (approx. 22 g/kg seed weight). It also contains a complex set of volatile compounds. The C. acaulis cypsela is, therefore, a valuable source of nutrients and bioactive substances

Carlina vulgaris

The methanol extracts from three populations of Carlina vulgaris L. were examined for the chlorogenic acid content, mineral content, total phenolic content (TPC), total flavonoid content (TFC), and antioxidant activity. Two populations originated from natural nonmetallicolous habitats (NN (populations from Nasiłów) and NP (populations from Pińczów)), and one metallicolous population (MB) was collected from Bolesław waste heap localized at the place of former open-cast mining of Ag-Pb and Zn-Pb ores dating back to the 13th century and 18th century, respectively. The level of Zn, Pb, Cd, Fe, Ni, and Mn was significantly higher in the root and leaves of MB plants as a result of soil contaminations compared to those of the NN and NP ones. The highest antioxidant potency has been showed by the plants growing in a nonmetallicolous habitat. The flower head extracts obtained from the nonmetallicolous populations also contained the largest amount of chlorogenic acid, whereas the lowest was determined in the roots (ca. 2–3.5 mg/g and 0.2–0.4 mg/g of air-dry weight, resp.). These studies provide important information on the influence of a habitat on the quality of herbal materials and the content of the biologically active primary and secondary metabolites

Impact of Biotic/Abiotic Stress Factors on Plant Specialized Metabolites

Plants are a group of organisms that have developed remarkable adaptations to merely exist in the environment [...

Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts

Due to the limited effectiveness of immunotherapy used as first-line monotherapy in patients with non-small-cell lung cancer (NSCLC), the concepts of combining classical immunotherapy based on immune checkpoint antibodies with other treatment methods have been developed. Pembrolizumab and atezolizumab were registered in combination with chemotherapy for the treatment of metastatic NSCLC, while durvalumab found its application in consolidation therapy after successful chemoradiotherapy in patients with locally advanced NSCLC. Exceptionally attractive, due to their relatively low toxicity and high effectiveness, are treatment approaches in which a combination of two different immunotherapy methods is applied. This method is based on observations from clinical trials in which nivolumab and ipilimumab were used as first-line therapy for advanced NSCLC. It turned out that the dual blockade of immune checkpoints activated T lymphocytes in different compartments of the immune response, at the same time affecting the downregulation of immune suppressor cells (regulatory T cells). These experiments not only resulted in the registration of combination therapy with nivolumab and ipilimumab, but also initiated other clinical trials using immune checkpoint inhibitors (ICIs) in combination with other ICIs or activators of costimulatory molecules found on immune cells. There are also studies in which ICIs are associated with molecules that modify the tumour environment. This paper describes the mechanism of the synergistic effect of a combination of different immunotherapy methods in NSCLC patients